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• The concept of a fungalImycotoxin etiology of gout/ 
hyperuricemia in humans was first reported by Costantini 
(1989) (1). Gout and/or hyperuricemia have been induced in 
animals by the fungal species Ustilago maydis, Chaetomium 
trilaterale, Saccharomyces cerversiae, and by the mycotoxins, 
aflatox'm, ochratoxin, oosporein, oxalic acid. Gout and/or 
hyperuricemia have been induced in humans by the yeast 
Candida utilis and by the fungal metabolites cyclosporin, 
ergotamine and penicillin. Gout is documented to be etio- 
logically linked to beer, a Saccharomyces fermented bever- 
age. Beers contain significant amounts of ochratoxin and 
large amounts (7 to 9 mg/dl of uric acid, a metabolite 
produced by the brewers's yeast Saccharomyces cen'ersiae. 
Consistent with the fungal etiology of gout and 
hyperuricemia, the mode of action of colchicine in the 
treatment of gout is antifimgal. Colchicine shares antitubulin 
activity with griseofulvin, a potent antifimgal antibiotic. 
Griseofiilvin is as equally effective in the treatment of gout as 
colchicine. Similarly, another antitubulin drug, vinblastine is 
also antifimgal and effective in the treatment of gout. All of 
the other drugs used to treat gout and/or hyperuricemia 
possess antifimgal activity (Costantini 1989). 
THE FUNGAL ETIOLOGY OF GOUT AMD 
HYPERURICEMIA 
•       Ustilago Maydis/Moldy Corn-Induced Gout. 
Jarmai (1925) (2) reported a goose which developed gout 
after eating moldy corn. Hutyra et al (1926) (3) noted that 
gout in birds was caused by the smut fungus Ustilago 
maydis, a common cause of moldy corn. U. maydis, as well 
as a number of other fungi in the food chain, produces the 
mycotoxin oosporein. 
Oosporein Induced Gout in Chickens And Tur- 
keys. Pegram et al (1981, 1982) (4,5) fed oosporein to 
chickens and turkeys. This induced severe articular and 
visceral gout. Neither hyperuricemia nor renal failure 
occured to account for gout. This induction of both visce- 
ral and articular gout in the same animal appears to end the 
ongoing dispute as to whether or not these are two separate 
disease entities. 
Fungus Induced Gout in Chickens (Chaetomium 
trilaterale). Manning and Wyatt (1984) (6) fed chickens 
corn contaminated with the oosporeinproducing fungus 
Chaetomium trilaterale. All infected birds developed acute 
tophaceous gout without either renal failure or 
hyperuricemia. 
Ochratoxin Induced Gout and Hyperuricemia. 
Ochratoxin-induced gout in chicks was reported by Peck- 
ham et al (1971) (7). Ochratoxin-induced hyperuricemia 
in chickens was shown by Kubena et al (1983) (8). Serum 
uric acid rose to 15.6 mg%. Ochratoxin is often present in 
the food chain and in beer (Nip et al 1975) (9). This 
findling of ochratoxin in beer corelates with the work of 
Gibson et al who found that beer was the most popular 
beverage consumed in a group of 61 gouty men. Nearly all 
of these gouty men were heavy beer drinkers with 41% 
drinking more than 2.5 liters of beer daily. 
Aflatoxin-Induced Gouty Tophi and Gouty 
Nephropathy in Monkeys. Aflatoxin is common in the 
food chain. Bourgeois et al (1971) (10) fed aflatoxinto the 
macaque and found numerous clusters of urate crystals, 
surrounded by inflammatory cells including giant cells, in 
the kidneys in 5 of 20 dosed macaques. In addition, the 
renal lesions were near-identical to those described by 
Sommers and Churg (1982) (11) in kidney biopsies of 
patients with chronic hyperuricemia and gout. 
Oxalic Acid-Induced Gout. Oxalic acid is a myco- 
toxin produced by many different fungal species. It was 
  
  
reported to induce gout in chickens by von Kossa (1899) 
(12). It is important to note that uric acid degrades to 
oxalic acid, a finding described by Wells (1914) (13). This 
explains why both oxalate and urate are both usually 
present in kidney stones which occur in gouty patients. 
Yeast Autolysate-Induced Hyperuricemia in Rats. 
Long-term feeding of rats with yeast autolysate has caused 
hyperuricemia associated with a rise in the level of anti- 
DNA antibodies (Nikolenko et al 1989) (14). These 
findings appeared to correlate with the finding of signifi- 
cantly elevated titres of anti-DNA in 70 of patients with 
primary gout. The elevated anti-DNA titres correlated 
with the severity of gouty arthritis and the severity of 
morphological renal manifestations of gout. The anti- 
DNA findings also correlated with blood B-lymphocyte 
counts and with other immunological indices. 
Yeast (Saccharomyces Fermented Beer and 
Wine)-Induced Gout In Humlans. Beer and or wine are 
the classical inducers of attacks of acute gout in humans. 
Ultraviolet microscopy has demonstrated uric acid, pu- 
rines, lysine and S-adenosylmethioline in the vacuoles of 
S. cerevisiae (Svihla et al 1963) (15). Beer and wine are 
fermentations of Saccharomyces cereversiae. Actually, 
drinking beer and wine is quite the same as drinking a 
fungal culture; all of the media, all if the remaining live 
fungus, all of the fungal antigenic cell wall and cellular 
contents, and all of its metabolites including not only the 
alcohol, but generous amounts of mycotoxins and uric 
acid. 
While all contemporary studies have attempted to 
implicate the alcohol in fermented beverages as the cause 
of hyperuricemia, the older literature contains references 
to the yeast cell content of beer. Ingestion of beer whose 
alcohol content had been completely removed by distilla- 
tion was still associated with large amounts of purine 
bodies being found in the urine (Lindsay 1913) (16). 
Preformed uric acid is present in large amounts in 
beer. The actual amounts of uric acid found in beer are 
summarized in Table I. 
Moreover, alcohol itself is immunotoxic, which 
increases the incidence of infections in general. The 
TABLE I. URIC ACID CONTENT OF VARIOUS BEERS 
 
combination of immunotoxic alcohol and mycotoxins in 
beer and wine probably represents synergism of a fungal/ 
mycotoxin etiology of gout and hyperuricemia. Large 
ammounts of ochratoxin, which causes gout and 
hyperuricemia in animals, has been found in beer by 
Krough et al (1974), Chu et al (1975), and Nipet al (1975) 
(17,18,19). Gibson et al. found in a group of 61 gouty men, 
that nearly all were found to be beer drinkers with 41% 
drinking more than 2.5 liters of beer daily. 
Candida Utilis Induced Hyperuricemia In Hu- 
mans Edozien et al (1970) (20) documented that feeding 
C. utilis to human subjects caused severe hyperuricemia. 
Their results are summarized in Table II. 
Rousch (1961) and Svihla (1959) (21,22) described 
the presence of uric acid and uric acid crystals in the 
 TABLE II. HYPERURICEMIC EFFECTS OF URIC ACID 
CONTAINING YEAST 
Baseline Before     45g Yeast      90g Yeast       135g Yeast 
__________Yeast Feeding       per day__   _per day__   _per day 
Serum Uric 
Acid (mg%)        4.5_______      _7.2___     __9.0____       _9.6____ 
cytoplasm of C. utilis. The existence of preformed uric 
acid and urate crystals in the cytoplasm of C. utilis 
provides proof of a fungal source of uric acid and pre- 
formed urate crystals, a finding quite similar to the finding 
of oxalic acid and oxalate crystals which originate from 
Aspergillus niger in aspergillomas found in humans. It was 
also determined that 5 grams of the yeast was found to 
contain 450 mg of uric acid. That it was indeed uric acid 
was chemically confirmed by the purified uricase method 
of Kalckar. A fungal etiology of urate crystals in gouty 
tophi is quite consistent with etiology of gout. 
Cyclosporin-Induced Gout In Humans. Cyclo- 
sporin is a fungal metabolite produced by Tolypociadium 
inflatum Gams. Cyclosporin-induced hyperuricemia and 
gout are being increasing reported by a number of organ 
transplant centers (Lin et 1989, West et al 1987,Gores et 
al 1988) (23,24,25). Gout has occured in as many as 24% 
of cyclosporin-treated patients. Most interestingly, none 
of the patients in four different series of transplantations 
in which the immunosuppressant azathioprine was used 
experienced a single episode of gout. This difference 
suggests that the induction of gout was not due to a 
mechanism involving suppression of the immune system. 
Cyclosporin and azathioprine are both cytotoxic 
agents, particularly against cells of the immune system. All 
cytotoxic agents possess antifungal activity. Cyclosporin 
has been documented to possess selective antifungal activ- 
ity against Cryptococcus (Mody et al 1989) (26). The 
remote possibility that the antifungal effect was in any way 
related to the immunosuppressant effects of Cyclosporin 
was essentially ruled out by their observation that the 
improved survival was noted in both immunologically 
intact and congenitally T-cell deficient mice. Cyclosporin 
dramatically increases the risk of infection in general and 
of fungi other than Cryptococcus. This appears to be simi- 
lar to the phenomena seen with therapeutic use of penicil- 
lin causing an overgrowth of other microbes including 
yeast infections. 
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Ergotamine-Induced Gout In Humans. Ergota- 
mine tartrate has been shown to cause acute attacks of gout 
in humans. Ergotamine is a fungal metabolite produced by 
Claviceps purpurea (Talbott 1964) (27). 
Penicillin-Induced Gout In Humans. Penicillin is 
a fungal metabolite produced by Penicillium notatum. It is 
known to induce acute attacks of gout in humans (Talbott 
1964). 
PREVIOUSLY POSTULATED MOD EOF ACTION 
OF COLCHICINE 
• If Etiology Is Unknown, Explaining Therapy Is 
Pure Speculation. There are very few absolute truisms in 
medicine. One which cannot be debatable is that when the 
cause of a disease is unknown, one simply cannot explain 
why.a particular drug is effective in treating that disease. 
Any and all explanations are entirely postulative. 
Explaining Antigout Therapy Has Been Entirely 
Postulative. Since the underlying etiology of gout and 
hyperuricemia has heretofore been unknown, all prior 
explanations of therapy have been purely postulative and 
have been based entirely upon the effects of drugs oh the 
two obvious manifestation of gout, inflammation and 
hyperuricemia. These postulates have led to the com- 
monly held perception that hyperuricemia results in crys- 
tal deposition which is the cause of the inflammation. This 
postulation is fatally flawed in that there is actually no 
consistent elevation of plasma uric acid levels and attacks 
of gout; urate crystals are omnipresent in gouty lesions; 
and, episodes of inflammation occurs only quite sporadi- 
cally-even years apart. Furthermore, the most effctive 
drug in treating an acute attack of gout is colchicine which 
has no effect upon uric acid nor is the drug antiinflammatory. 
In addition, there is the problem that the dnigs which lower 
plasma uric acid levels do not relieve an acute attack of 
gout. 
 Previously Postulated Mode of Action of Colch- 
icine. The actual mechanism of action of colchicine in the 
treatment of gout has remained unknown. This state of 
      events is most certainly not due to a paucity of studies 
either in clinical medicine nor in the basic biological 
sciences. Colchicine has captured the attention of a broad 
       array of scientists around the world and over a quite long 
period of time. Its dramatic and easily visualized effect on 
the cellular spindle has been the subject of considerable 
investigation. Yet, despite all of this attention, the mecha- 
nism of its dramatic action in treating an acute attack of 
gout has continued to remain one the great mysteries of 
medical science. 
 The presently held theory of the mechanism of 
action of colchicine in gout is one of cytotoxic immunosup- 
pression resulting in an antiinflammatory effect. This 
concept is based upon in vitro studies of the effect of toxic 
doses of colchicine upon white blood cells and these types 
of toxicological studies have resulted in the following 
scenario: 
Colchicine arrests cell mitosis in the metaphase, 
due to failure of spindle formation, and may 
prevent cells from entering mitosis. Colchicine 
has the same effects on the leukocytes incapable 
of responding to the toxicity of urate crystals. It is 
this intereference with the immune system re- 
sponsiveness of the acute gouty granulomatous- 
type inflammatory reaction which gives the pa- 
tient relief of his inflammation. 
The scenario is supported by data such as colchicine 
inhibits leukocyte adhesiveness (Malawista 1965) (28) 
amoeboid motility (Malawista 1965) (29), mobilization 
(Fruhman 1960) (30), chemotaxis (Phelps 1970) (31), 
degranulation of lysosomes (Rajan 1966) (32), and leuko- 
cyte metabolism during phagocytosis (Goldfinger 1965, 
Wechsler et al 1965) (33, 34). The most potent inhibitory 
effects of colchicine are on chemotaxis (Phelps 1970) (35) 
and random motility of leukocytes under the influence of 
urate (Phelps 1969) (36). However, in order to produce 
any of these findings, it is necessary to give, per unit mass 
of experimental material, up to approximately 100 times 
the therapeutic dose which is effective in gouty patients 
(Talbott 1965). 
Several clinical studies have documented that the 
leukocytes are not actually affected by colchicine admin- 
istered to patients in therapeutic levels. Colchicine in 
clinically effective doses produced no detectable ultra- 
structural changes in the leukocytes in synovial biopsies of 
patients with acute gouty arthritis (Agudelo and 
Schumacher 1973) (37). In patients treated with 0.6 to 1.8 
mg per day of colchicine to prevent recurrences of familial 
Mediterranean fever, neutrophils were capable of normal 
phagocytosis, produced normal amounts of pyrogen, and 
migrated normally, both randomly and in response to 
chemotactic stimuli (Dinarello et al 1976) (38). Further- 
more, colchicine failed to influence the behavioural re- 
sponses to the irritating effects of urate crystals in urate 
arthritis induced by injecting urates into the ankle joint of 
rats (Coderre and Wall 1988) (39). 
Obviously, the postulate that colchicine is 
antiinflammatory by restricting the function of neutrophils 
has been essentially disproved in both animals and in 
humans. 
AHTIGOUT AMD ANTIFUNGAL ACTIVITY OF 
COLCHICINE 
•       Antigout Effectiveness of Colchicine. Colchicine 
is a plant alkaloid whose benefit in the treatment of gout 
is recorded in the most ancient medical records. Early 
descriptions of its use leave little doubt of its effectiveness: 
" In the first trial of the medicine, it (colchicine) 




short cure; removing the paroxysm as by a charm, 
and not infrequently without any very sensible 
operation upon the stomach, or upon any of the 
excreting organs". 
Scudmore (1817) (40) 
Colchicine has always been, and still is, the most 
specific treatment for acute gouty attacks (Ahern et al 
1987) (Famaey 1988) (41) (42). Even the administration 
of anti-urate drugs often requires the addition of colch- 
icine to control continuing acute attacks of gout. 
Antifungal Activity of Colchicine. Colchicine is a 
plant-derived alkaloid. Such alkaloids are anti-predator 
and antifungal in their actions as plant protectors. (Mothes 
et al 1988) (43). 
The antifungal activity of Colchicine against As- 
pergillus niger was documented by Shankhla and Sharma 
(1969) (44). Other reported data demonstrating the anti- 
fungal activity of colchicine was reviewed by Egisti and 
Dustin (1955) (45). This data is summarized in Table III. 
TABLE III. ACTION OF COLCHICINE ON FUNGI 
Species_________________Results 
Recently, in a murine Candida study comparing the 
results of intravenous phorbol myristate acetate and 
intrapertional colchicine, both drugs completely elimi- 
nated the epidermal neutrophilic infiltrates characteristic 
of these infections (Sohnle and Hahn 1989) (46). The 
resultant degree of Candida invasion into the dermis was 
very significant in the phorbol myristate acetate treated 
animals but quite minimal in the colchicine treated ani- 
mals. The results are quite indicative of the in vivo 
antifungal protective effect of colchicine. 
The fact that colchicine is an antitubulin drug which 
shares this mode of action with the antifungal antibiotic 
griseofulvin has been entirely ignored in the clinical appli- 
cations of colchicine. 
We have here a situation where the major mode of 
action of these two drugs, sharing no other apparent 
action, has been entirely ignored in understanding the 
clinical effectiveness of one of the drugs, colchicine. The 
extent of this error of perception becomes quite apparent 
in the light of the observation that griseofulvin, a specific 
antifungal antibiotic possessing no other significant phar- 
macological property, is equally as effective as colchicine 
in relieving an acute attack of gout. 
ANTIGOUT AMD AHTIFUHGAL ACTIVITY OF 
GRISEOFULVIH 
• Antigout Effectiveness of Griseofulvin. There are 
two reports in the medical literature of dramatic responses 
of acute gout to the specific antifungal agent griseofulvin. 
Both reports appeared in 1962 and there have been no 
additional followup studies reported since that time. 
The rational for these trials was that gouty patients 
given griseofulvin for superficial fungal infections ob- 
served that their painful joints had also markedly im- 
proved. 
In the first study, the use of moderate to high doses 
of griseofulvin to treat acute gouty arthritis resulted in 
complete remissions in 14, partial remission in 2, out of 23 
patients within 24 to 48 hours (Slonim et al 1962) (47) .There 
were 23 patients with acute gouty arthritis in the series. 
Included were histologic proof of tophi in 15 patients; 
dramatic clinical improvement in 22 patients during colch- 
icine trial administered by standard technic for a previous 
acute attack in 12; two or more serum uric acid levels 
greater than 6,5 mg, per cent in 22 cases; and x-ray 
evidence of bone destruction in 17 of the group. Side 
effects were negligible but 6 out of the 7 patients who did 
not improve suffered vomiting episodes during the period 
of drug dosing and were felt to not have retained therapeu- 
tic amount of the drug. 1.0 to 4.0 g. of griseofulvin was 
given orally at the onset of the study to the gouty patients, 
with further dosage at 6 hours spacings. Eighteen of these 
patients recived 4 to lOg total dosage during the first day 
and 0 to 6 g on the second. Higher doses were prescribed 
for 5 patients to demonstrate, if possible, an effect on 
serum and urine uric acid concentrations; none was seen. 
In the second report, 20 patients with acute gout 
were treated and favorable improvement was noted in 15 
(Wallace and Nissen 1962) (48). Once again,, the optimal 
response occured within 24 to 48 hours. Patients were 
given 6-10 g of griseofulvin in divided doses. 
Antifungal Activity of Griseofulvin. Griseofulvin 
is a specific antifungal antibiotic. It was first isolated from 
Penicillium griseofuvium dierckx in 1939 (Oxford et al) 
(49), but it was not investigated further at that time 
because it lacked antibacterial activity. In 1946 Brian et al 
(50) found a metabolite in Penicilium janczewskii which 
caused shrinking and stunting of fungal hyphae. They 
named this "curling factor" which was subsequently found 
to be griseofulvin. During the next decade, it was widely 
used to treat a variety of fungal diseases of plants and 
ringworm of cattle. Its potential for the treatment of human 
infections was not realized until Gentles (1958) (51), 
searching for potential therapeutic agent to control fungal 
infections in Scottish miners, demonstrated that oral 
griseofulvin was effective in experimental Microsporum 
canis infection of guinea pigs. It was soon shown that the 
drug was also effective in human ringworm infections 
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(Williams et al 1958, Blank et al 1959) (52,53). Griseofulvin 
is now generally accepted as the drug of choice for 
treatment in the majority of these fungal diseases. 
AHTIGOUT AMD ANTIFUNGAL ACTIVITY OF VINBLASTIHE 
• Antigout Effectiveness of Vinblastine. Another 
member of the antimicrotubule group of agents effective 
in treating gout is vinblastine. It has been demonstrated to 
be as effective as colchicine in the treatment of acute gout 
(Krakoff 1965) (54). 
Antifungal Activity of Vinblastine. In 1983, the 
similarity of actions of vinblastine, griseofulvin and colch- 
icine was demonstrated in a unicellular alga. Electron 
microscopy demonstrated conspicuous mohpological ab- 
normalities resulting from inhibition of microtubule de- 
pendent protoplasmic streaming (Mizukami and Wada 
1983) (55). The authors noted that very similar changes 
had been previously reported in Fusarium acuminatum 
treated with another antimicrotubule agent, methyl ben- 
zimidazole-2-ylcarbamate. 
It should be noted that the latter compound is an 
azole and that the azoles are evolving as a most promising 
group of antifungal agents with several members of the 
group in current use (ketoconazole, fluconazole, etc.) and 
a number of others are near-ready for marketing. 
CONCLUSION 
• The unified concept of a fungal etiology and an 
antifungal mode of action of antigout drugs provides a 
clinically meaningful therapeutic drug and dietary ap- 
proach not only for the physician, but, most importantly, 
for the patient afflicted with gout, particularly those who 
are been drinkers and are consuming other yeast-fer- 
mented beverages and foods such as wine, bread and 
cheese. 
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